PubRank

Efficacy Study of Ipilimumab Versus Placebo to Prevent Recurrence After Complete Resection of High Risk Stage III Melanoma

Clinical Trial ID NCT00636168

PubWeight™ 30.57‹?›

🔗 Visit the ClinicalTrials.gov page for NCT00636168

Top papers

Rank Title Journal Year PubWeight™‹?›
1 Prolonged Survival in Stage III Melanoma with Ipilimumab Adjuvant Therapy. N Engl J Med 2016 3.46
2 Systematic review of medical treatment in melanoma: current status and future prospects. Oncologist 2011 2.89
3 Adjuvant ipilimumab versus placebo after complete resection of high-risk stage III melanoma (EORTC 18071): a randomised, double-blind, phase 3 trial. Lancet Oncol 2015 2.80
4 Antibody-based therapeutics to watch in 2011. MAbs 2011 2.00
5 Antibodies to watch in 2010. MAbs 2010 1.90
6 CTLA-4 blockade in tumor models: an overview of preclinical and translational research. Cancer Immun 2013 1.71
7 Immune monitoring of the circulation and the tumor microenvironment in patients with regionally advanced melanoma receiving neoadjuvant ipilimumab. PLoS One 2014 1.37
8 Dabrafenib and its potential for the treatment of metastatic melanoma. Drug Des Devel Ther 2012 1.16
9 Immunomodulatory therapy for melanoma: ipilimumab and beyond. Clin Dermatol 2013 1.04
10 Safety, correlative markers, and clinical results of adjuvant nivolumab in combination with vaccine in resected high-risk metastatic melanoma. Clin Cancer Res 2014 1.01
11 Treatment of cutaneous melanoma: current approaches and future prospects. Cancer Manag Res 2010 1.01
12 Clinical impact of checkpoint inhibitors as novel cancer therapies. Drugs 2014 0.99
13 MHC-based detection of antigen-specific CD8+ T cell responses. Cancer Immunol Immunother 2010 0.98
14 Immune checkpoint inhibitors in clinical trials. Chin J Cancer 2014 0.98
15 New combinations and immunotherapies for melanoma: latest evidence and clinical utility. Ther Adv Med Oncol 2013 0.92
16 Immune checkpoint blockade in cancer treatment: a double-edged sword cross-targeting the host as an "innocent bystander". Toxins (Basel) 2014 0.92
17 What is new in the treatment of advanced melanoma? State of the art. Contemp Oncol (Pozn) 2012 0.88
18 A miRNA-Based Signature Detected in Primary Melanoma Tissue Predicts Development of Brain Metastasis. Clin Cancer Res 2015 0.88
19 Beyond cancer vaccines: a reason for future optimism with immunomodulatory therapy. Cancer J 2011 0.86
20 Implementing combinatorial immunotherapeutic regimens against cancer: The concept of immunological conditioning. Oncoimmunology 2014 0.84
21 Antibody therapies for melanoma: new and emerging opportunities to activate immunity (Review). Oncol Rep 2014 0.82
22 Tumor PD-L1 expression, immune cell correlates and PD-1+ lymphocytes in sentinel lymph node melanoma metastases. Mod Pathol 2015 0.77
23 Malignant Melanoma. Healthcare (Basel) 2013 0.75
24 Adjuvant therapy for high-risk melanoma. EJC Suppl 2013 0.75
Next 100